EL: Smart Eyewear Capacity Expansion Will Drive Future Bullish Thesis

EssilorLuxottica Société anonyme's updated analyst price target edges slightly lower to about €316, reflecting analysts' recent target cuts in the €10 to €24 range, alongside broadly steady assumptions for growth, margins and future P/E.

Analyst Commentary

Recent Street research on EssilorLuxottica Société anonyme clusters around reduced price targets, with one upgrade, pointing to a more balanced stance on the stock rather than a uniform shift in sentiment.

Bullish Takeaways

Bullish analysts continue to see upside versus current levels, as several targets, including the revised €320 level, still sit above the updated average of about €316. This suggests confidence that current earnings assumptions can support a premium P/E.
The recent upgrade from a major house signals that some see execution on the core eyewear and optical businesses as solid enough to support growth assumptions that underpin existing valuation frameworks.
Targets being adjusted in relatively contained steps of €10 to €24, rather than more aggressive changes, indicate that analysts are tweaking models rather than making sweeping revisions to long term growth or margin expectations.
Maintaining positive ratings alongside modest target reductions suggests that, for bullish analysts, recent changes are more about fine tuning discount rates or multiples than questioning the fundamental equity story.

Bearish Takeaways

Multiple price target cuts in quick succession, including those of €10, €24 and the move to €320 from €340, point to increased caution on how much investors should be willing to pay for the shares at prior valuation levels.
Bearish analysts appear more conservative on the sustainability of previous P/E assumptions. This can cap near term re rating potential if the company does not deliver against existing growth and margin expectations.
The clustering of target reductions from several banks suggests a shared view that earlier valuation frameworks may have been too optimistic, even if earnings forecasts remain broadly intact.
For investors, the slightly lower consensus target around €316 can be read as a signal that upside expectations are now more restrained, which raises the bar for future execution to justify any higher multiple expansion.

What's in the News

Meta and EssilorLuxottica are in talks to potentially double smart glasses production capacity by the end of this year, with discussions reportedly including annual capacity of 20m units by the end of 2026 and the capability to provide over 30m units if demand supports it (Bloomberg).
Meta and EssilorLuxottica are having internal debates over pricing and promotion for Ray-Ban Meta smart glasses as demand surges, with discussions described as a push and pull but within a constructive partnership (Bloomberg).
Meta and EssilorLuxottica face a lawsuit from Solos Technology related to smart glasses patents, adding a legal angle to the smart eyewear segment (Bloomberg).
Regulatory issues are in focus as Meta's Ray-Ban smart glasses release has been withheld from the EU, which affects the timing of availability in that market (Bloomberg).
EssilorLuxottica and Dolce&Gabbana extended their eyewear license agreement through 2050 for prescription frames and sunglasses, maintaining a long running fashion partnership for the long term (company announcement).

Valuation Changes

Fair Value: €316.59 to about €316.45, a very small move lower that keeps the implied value effectively unchanged.
Discount Rate: 7.39% to about 7.41%, a slight increase that points to a marginally higher required return in the model.
Revenue Growth: 9.75% to about 9.93%, a small upward adjustment to the implied € revenue growth assumption.
Net Profit Margin: 9.82% to about 9.87%, a modest uplift in projected € earnings as a share of sales.
Future P/E: 49.74x to about 49.22x, a slight reduction in the multiple applied to forward earnings.

19 views

Key Takeaways

Ongoing innovation in vision solutions and smart eyewear, along with strategic acquisitions, enhances competitive advantage and supports future market share and profitability.
Global expansion, supply chain diversification, and direct-to-consumer initiatives drive top-line growth, operational resilience, and recurring revenue opportunities.
Heavy investment in innovative eyewear and premium segments exposes EssilorLuxottica to technology, regulatory, economic, and margin risks amid intensifying competition and global cost pressures.

Catalysts

About EssilorLuxottica Société anonyme

Designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, the Middle East, Africa, Europe, Latin America, and the Asia-Pacific.What are the underlying business or industry changes driving this perspective?

Strong pipeline of innovation in myopia management solutions (Stellest 2.0, DOT technology) and leadership in addressing rising vision disorders among children globally positions EssilorLuxottica to capture outsized growth from increasing myopia incidence, directly supporting future revenue and market share gains.
Expanding global presence, especially in Asia and Latin America, leverages the growing middle class and improved healthcare access in emerging markets, opening new high-growth channels and supporting sustained top-line expansion.
Investments in smart eyewear, AI-enabled vision solutions, and MedTech (Ray-Ban Meta, Oakley Meta, Nuance Audio, acquisition of Optegra Eye Clinics) capitalize on long-term demand for technologically advanced and personalized eye health platforms, catalyzing product mix upgrades and higher ASPs, which will benefit gross margin and future earnings.
Ongoing vertical integration and supply chain diversification (new production facilities in France, Thailand, Laos, Mexico) improve operational efficiency and mitigate tariff/regulatory headwinds, preserving or expanding operating margins and providing resilience to exogenous shocks.
Accelerating direct-to-consumer and subscription-based channels (notably in Europe and North America), plus deeper engagement with healthcare professionals, enable stronger customer acquisition, higher recurring revenues, and long-term margin improvement, supporting net income and cash flow growth.

EssilorLuxottica Société anonyme Earnings and Revenue Growth

EssilorLuxottica Société anonyme Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming EssilorLuxottica Société anonyme's revenue will grow by 9.9% annually over the next 3 years.
Analysts assume that profit margins will increase from 8.1% today to 9.9% in 3 years time.
Analysts expect earnings to reach €3.7 billion (and earnings per share of €8.12) by about March 2029, up from €2.3 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as €4.6 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 49.3x on those 2029 earnings, up from 39.4x today. This future PE is greater than the current PE for the GB Medical Equipment industry at 24.5x.
Analysts expect the number of shares outstanding to grow by 0.44% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.41%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The rapid shift towards disruptive optical technologies, such as smart eyewear and AI-enabled glasses, carries substantial execution and adoption risks-if EssilorLuxottica is unable to maintain product relevance, successfully commercialize innovations, or keep pace with technology leaders, it could suffer from slower revenue growth and margin dilution, especially as wearables have been acknowledged as margin dilutive despite their sales momentum.
Intensifying global tariff headwinds and persistent inflationary pressures (notably in the U.S. market) could erode gross margins and net income, with recent results already showing 80-90 basis points of margin dilution and management warning that mitigation strategies like price increases and supply chain relocation may only gradually offset these costs.
The company's aggressive investment in MedTech and a growing assortment of premium/luxury segments (e.g., AI glasses, Stellest lenses, hearing aid eyewear) could make it increasingly vulnerable to economic downturns and cyclical spending contractions, thus exposing revenues and profitability to swings in discretionary consumer income and global macro risks.
EssilorLuxottica's reliance on being the market leader in emerging medical and wearable categories heightens its exposure to tightening regulatory scrutiny and slow or fragmented reimbursement/approval processes (e.g., FDA approval for Stellest lenses), potentially delaying new revenue streams and pressuring earnings if regulatory hurdles or commercialization setbacks occur.
The ongoing expansion of integrated, direct-to-consumer channels and major retail rollouts raises the risk of operational complexity and execution missteps, while at the same time global e-commerce and lower-cost competitors are driving greater price transparency and margin compression-pressuring EssilorLuxottica's long-term revenue growth and its ability to sustain premium pricing.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of €316.45 for EssilorLuxottica Société anonyme based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €365.0, and the most bearish reporting a price target of just €180.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €37.8 billion, earnings will come to €3.7 billion, and it would be trading on a PE ratio of 49.3x, assuming you use a discount rate of 7.4%.
Given the current share price of €197.7, the analyst price target of €316.45 is 37.5% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on EssilorLuxottica Société anonyme?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

EL: Expansion Into New Optical Markets Will Drive Measured MedTech Momentum